Noble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report) today and set a price target of $14.00. The company’s shares closed yesterday at $2.11.
According to TipRanks, LeBoyer is an analyst with an average return of -5.8% and a 28.73% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, MAIA Biotechnology, Inc., and Tonix Pharma.
MAIA Biotechnology, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $9.64 and a one-year low of $2.12. Currently, MAIA Biotechnology, Inc. has an average volume of 58.97K.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MAIA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company’s lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Read More on MAIA:
